No profile data available.
ProMIS Neurosciences, Inc. (PMN) is a healthcare company in the brain and nerve treatment drugs industry, based in Toronto, Canada, with about 10 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$39.72 million. Its market capitalization was $86.18 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
ProMIS Neurosciences reported $0 in revenue for fiscal year 2025.
$86.18 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include NRx Pharmaceuticals, Inc. (NRXP), Coya Therapeutics, Inc. (COYA), Neumora Therapeutics, Inc. (NMRA), Cognition Therapeutics, Inc. (CGTX).